Search the Newsreel

Tango Therapeutics, Inc. Q2 2026: Revenue $0 Net loss $55.34M, EPS ($0.37) — 10-Q Summary

Tango Therapeutics, Inc. reported Q2 2026 financial results with $0 revenue, a net loss of $55.34 million, and a diluted EPS loss of $0.37. The company's financial performance worsened year-over-year due to increased spending on its PRMT5 programs and expanded clinical operations. Despite the …

Tango Therapeutics (Nasdaq: TNGX) posts higher loss while amassing $1B cash for oncology trials

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics announced its second-quarter 2026 financial results, highlighting a pivotal period with positive Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer, achieving a 92% objective response rate. The company is preparing for late-stage clinical advancement and has strengthened its leadership team …

Contango Silver & Gold Inc. (CTGO) Earnings Preview — What to Watch Before the Report

345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. recently acquired 345,156 shares of Tango Therapeutics (NASDAQ:TNGX) worth approximately $10.79 million, giving them a 0.24% stake in the company. Other institutional investors also adjusted their positions in Tango Therapeutics, while insider Adam Crystal sold 27,000 shares for about $798,930. …

(ANGO) Price Dynamics and Execution-Aware Positioning

This article from Stock Traders Daily provides an AI-driven analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and significant upside potential due to a lack of resistance levels. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk …

Cango Inc (CANG) Stock News Today

This article provides an update on Cango Inc (CANG) stock, noting its current trading price of $1.670, up 3.14%. It states that more news regarding the company's stock, earnings, analyst ratings, and key developments will be available soon. The page serves as a hub …

Cango Inc (CANG) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cango Inc (CANG) has an earnings forecast score of 8.00, ranking 104 out of 483 in the Software & IT Services industry, with an average price target of $4.00 based on 2 analysts. Analysts generally recommend a "Buy" for CANG stock, anticipating future EPS …

AngioDynamics, Inc. (ANGO) stock price, news, quote and history

This article provides comprehensive financial information for AngioDynamics, Inc. (ANGO), including its current stock price, trading activity, key financial metrics, and an overview of its medical technology products. It also features performance comparisons against the S&P 500, earnings trends, analyst ratings, and a list …

Form 8K Tango Therapeutics Inc For: 7 August By Investing.com

This article announces that Tango Therapeutics Inc. filed a Form 8K on August 7th. It is a brief financial news update from Investing.com, highlighting the filing with the Securities and Exchange Commission (SEC). The article also notes a 6.66% decline in Tango Therapeutics' stock …

Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure

Tango Therapeutics announced that Executive Chair Dr. Barbara Weber's employment ended on August 3, 2026, and she resigned from all positions without disagreement. Her departure aligns with an amended employment agreement, and she will receive a separation package including salary continuation, COBRA reimbursement, and …

Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?

Tango Therapeutics (NASDAQ:TNGX) experienced a 6.1% decline in its share price during midday trading, closing at $27.24 with a significant 86% decrease in trading volume compared to its average. Despite the drop, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an …

Tango Therapeutics (NASDAQ: TNGX) outlines Barbara Weber separation package

Tango Therapeutics (NASDAQ: TNGX) has detailed the separation agreement with its former Executive Chair, Dr. Barbara Weber, whose employment and board roles ended on August 3, 2026. The agreement, executed on August 6, 2026, includes base-salary severance and COBRA reimbursement through December 31, 2026, …

Sangoma Technologies Corp (SANG) Earnings Forecast: Future EPS & Revenue Growth Estimates

AngioDynamics SmartPort Infection Lawsuit Alleges Defective Port Caused Sepsis

A Pennsylvania man has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that a defective SmartPort catheter caused a severe infection and sepsis, necessitating its surgical removal. The complaint claims that defects in the port catheter promoted bacterial growth and that the companies …

Mangoceuticals, Inc. (MGRX) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Mangoceuticals, Inc. (MGRX) stock, including its current price, historical data, financial metrics, and company profile. MGRX is engaged in the development and sale of men's wellness products through a telemedicine platform, offering brands like Mango, …

State Street (NYSE: STT) discloses 7.6% holding in Contango Silver & Gold

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU With New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Nuclea Energy Inc., a merger partner of Mangoceuticals, has signed a Memorandum of Understanding with New Mining Co. to collaborate on the deployment of behind-the-meter modular reactors for high-density computing infrastructure. This partnership aims to provide reliable, carbon-free, and cost-effective power solutions for data …

Certain Stock Options of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026.

Certain stock options of Tango Therapeutics, Inc. (TNGX) are under a 60-day lock-up agreement, preventing sales or transfers from June 9, 2026, until August 8, 2026. This restriction applies to directors and executive officers and covers common stock and convertible securities. The agreement aims …

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics (ANGO) faces a trade-off between its rapidly expanding Med Tech platforms and persistent margin pressure from tariffs and rising operating costs. While NanoKnife, Auryon, and AlphaVac show strong growth potential and strategic importance, the company's valuation is mixed, and a Zacks Rank #4 …

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics, Inc. ANGO has set an initial fiscal 2027 framework that keeps its Med Tech transformation at the center of the investment case. Faster growth from its priority platforms is expected to lift sales, but margin pressure and continued losses remain material constraints. The …

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics (ANGO) shares have significantly outperformed the market, gaining 33.5% in three months, driven by its shift towards higher-margin Med Tech platforms like NanoKnife and Auryon. While Med Tech growth and product differentiation support the company's momentum, concerns about valuation, tariff impact on earnings …

Tango Therapeutics executive chair Barbara Weber steps down, exits board

Barbara Weber has stepped down as Executive Chair of Tango Therapeutics and exited her board seat, effective August 3, 2026. The company stated that her departure was not due to any disagreements regarding company operations, practices, or policies. This news was generated by AI …

Zacks Research Reduces Earnings Estimates for AngioDynamics

Bitcoin miner explores modular reactors for up to 100 MWe

Mangoceuticals announced that its merger partner, Nuclea Energy Inc., signed a non-binding MOU with New Mining Co. to assess the deployment of Nuclea's modular reactor technology for New Mining's high-density computing and Bitcoin mining operations. The evaluation will proceed in phases, starting with engineering …

Mangoceuticals (MGRX) merger partner Nuclea inks Utah nuclear test reactor MOU

Mangoceuticals, Inc. announced that its merger partner's subsidiary, Nuclea Energy USA Inc., signed a memorandum of understanding (MOU) with the Utah Office of Energy Development. This MOU aims to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab to advance …

Why is Mangoceuticals stock surging today?

Mangoceuticals (MGRX) stock surged over 31% in pre-open trading after its merger partner, Nuclea Energy Inc., announced a key regulatory milestone for its Morpheus microreactor program. This development involves a memorandum of understanding to explore siting a nuclear test reactor in Utah, bolstering investor …

Bango chair Darcy Antonellis on governance, growth and opportunity

Bango PLC (AIM:BGO, OTCQX:BGOPF) non-executive chair Darcy Antonellis talks to Proactive's Stephen Gunnion about her background, why she joined Bango, and how she sees the company's opportunity as the subscription economy evolves. Drawing on senior leadership experience at Warner Bros. and Vubiquity, she explains …

Mangoceuticals Wins Nasdaq Extension Amid Nuclea Deal Progress

Mangoceuticals (MGRX) has received a second 180-day extension from Nasdaq, pushing its compliance deadline to February 1, 2027, to restore its stock price above $1.00. This extension provides flexibility as the company advances a definitive business combination agreement with Nuclea Energy Inc., an advanced …

Utah Lab and Nuclea Explore Morpheus Test-Reactor Site

Mangoceuticals' merger partner, Nuclea Energy USA, has signed a Memorandum of Understanding (MOU) with the Utah Office of Energy Development to explore siting a nuclear test reactor for its Morpheus microreactor at the Utah San Rafael Energy Lab. This agreement is a significant step …

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why

Mangoceuticals (MGRX) stock surged over 49% after hours following news that its merger partner, Nuclea Energy Inc., through its subsidiary Nuclea Energy USA Inc., signed a memorandum of understanding with Utah's Office of Energy Development. This MOU explores siting a nuclear test reactor for …

Tango Therapeutics stock surges 45% on pancreatic cancer data

Tango Therapeutics' stock surged 45% after announcing positive initial data from its Phase 1/2 trial for a pancreatic cancer treatment. A combination of vopimetostat and daraxonrasib showed a 92% objective response rate and 90% 6-month progression-free survival in patients with MTAP-deleted and RAS-mutant pancreatic …

Tango Therapeutics, Inc. (TNGX) president exercises options and sells shares

Crystal Adam, President, R&D at Tango Therapeutics, Inc. (TNGX), exercised stock options for 27,000 shares at $5.20 each and simultaneously sold all 27,000 shares in two tranches at weighted average prices of $26.7895 and $27.3509 per share. These transactions were executed under a Rule …

Wondering what's happening in today's after-hours session?

This article provides an overview of the top gainers and losers in the US after-hours trading session on Wednesday, August 5, 2026. It highlights several companies, including MANGOCEUTICALS INC (MGRX) and CREATIVE MEDICAL TECHNOLOGY (CELZ) as top gainers, and YXT.COM GROUP HOLDING LTD (YXT) …

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Mangoceuticals' merger partner, Nuclea Energy, has signed a Memorandum of Understanding (MOU) with the Utah Office of Energy Development to explore siting a nuclear test reactor for its Morpheus microreactor at the Utah San Rafael Energy Lab. This partnership aims to advance the research, …

Q3 EPS Estimates for AngioDynamics Reduced by Zacks Research